Grouping lupus patients by subtype to study heart and blood vessel risk
Studies patients with lupus, grouped by antibodies, genes or biomarkers, compared with healthy people.
Plain-language title generated from the registry record
Registry title: Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
Key facts
- Where
- Stockholm, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07102030, who can take part
Where in Sweden
- Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Stockholm
- Trial code
- NCT07102030
- Record updated
- 3 August 2025
- Original description
The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are:Read full original descriptionShow less
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are:
A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease.
B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank.
Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.
Inclusion: SLE according to criteria (ACR82 or SLICC 2012) and consenting to participate.
Exclusion: Not possible to read and understand patient information due to language barriers or psychological/psychiatric disorders Not consenting; -.